A Study to Evaluate Safety, Side Effects, Muscle Activity and Speed of Gastric Emptying of GSK962040

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

September 10, 2007

Primary Completion Date

June 27, 2008

Study Completion Date

June 27, 2008

Conditions

Gastroparesis

Interventions

DRUG

GSK962040

GSK962040 will be supplied in the following tablet strengths: 1 milligram, 5m milligrams, 25 milligrams, 125 milligrams.

DRUG

Placebo

Subjects will receive placebo.

Trial Locations (1)

GSK Investigational Site, Leuven